| An oral antisense oligonucleotide for PCSK9 inhibition P Gennemark, K Walter, N Clemmensen, D Rekić, CAM Nilsson, ... Science Translational Medicine 13 (593), eabe9117, 2021 | 102 | 2021 |
| AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval D Rekić, I Azarov, J Knöchel, V Sokolov, C Nilsson, L Wernevik, D Han, ... British Journal of Clinical Pharmacology 88 (11), 4839-4844, 2022 | 13 | 2022 |
| Understanding and reducing complex systems pharmacology models based on a novel input–response index J Knöchel, C Kloft, W Huisinga Journal of pharmacokinetics and pharmacodynamics 45, 139-157, 2018 | 12 | 2018 |
| Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans E Ericson, L Bergenholm, AC Andréasson, CI Dix, J Knöchel, SF Hansson, ... Hepatology Communications 6 (10), 2689-2701, 2022 | 11 | 2022 |
| Etesian: a phase 2B study of the efficacy, safety and tolerability of Azd8233, a Pcsk9-targeted antisense oligonucleotide, in patients with dyslipidemia MJ Koren, A Hofherr, J Schumi, D Rekic, J Knochel, CAM Nilsson, ... Journal of the American College of Cardiology 79 (9_Supplement), 1475-1475, 2022 | 11 | 2022 |
| Design of FLAIR: a phase 2b study of the 5-lipoxygenase activating protein inhibitor AZD5718 in patients with proteinuric CKD HJL Heerspink, G Law, K Psachoulia, K Connolly, C Whatling, H Ericsson, ... Kidney International Reports 6 (11), 2803-2810, 2021 | 10 | 2021 |
| Deriving mechanism‐based pharmacodynamic models by reducing quantitative systems pharmacology models: An application to warfarin U Falkenhagen, J Knöchel, C Kloft, W Huisinga CPT: pharmacometrics & systems pharmacology 12 (4), 432-443, 2023 | 9 | 2023 |
| Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study E Prescott, O Angerås, D Erlinge, EL Grove, M Hedman, LO Jensen, ... International Journal of Cardiology 365, 34-40, 2022 | 9 | 2022 |
| AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia: Results from a randomized, single-blind, placebo-controlled phase 1 trial R Vega, P Garkaviy, J Knöchel, A Barbour, A Rudvik, J Laru, L Twaddle, ... Atherosclerosis 395, 2024 | 7 | 2024 |
| A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II J Knöchel, C Nilsson, B Carlsson, L Wernevik, A Hofherr, P Gennemark, ... CPT: pharmacometrics & systems pharmacology 11 (12), 1569-1577, 2022 | 6 | 2022 |
| Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects J Knöchel, K Nelander, M Heijer, EL Lindstedt, GB Forsberg, C Whatling, ... Clinical Drug Investigation 41, 895-905, 2021 | 5 | 2021 |
| Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD8233, targeting PCSK9, in patients with dyslipidemia A Hofherr, CA Nilsson, D Rekic, J Knoechel, R Goldwater, D Han, J Kusnir, ... Circulation 144 (Suppl_1), A9747-A9747, 2021 | 4 | 2021 |
| An Oral Antisense Oligonucleotide for PCSK9 Inhibition in Humans P Gennemark, K Walter, N Clemmensen, D Rekic, C Nilsson, J Knoechel, ... Circulation 142 (Suppl_3), A13307-A13307, 2020 | 3 | 2020 |
| A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the … J Knöchel, V Panduga, K Nelander, M Heijer, EL Lindstedt, H Ali, M Aurell, ... British Journal of Clinical Pharmacology, 2024 | 2 | 2024 |
| A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Dose Ranging Study of Atuliflapon in Participants with Proteinuric CKD: FR-PO979 HJ Heerspink, M Ufnal, CG Law, CA Whatling, HI Ericsson, J Knöchel, ... Journal of the American Society of Nephrology 34 (11S), 677-678, 2023 | 2 | 2023 |
| Pro-C3 but not PC3X is increased with advanced fibrosis stage in a longitudinal cohort of non-alcoholic fatty liver disease (NAFLD) patients J Knochel, S Kechagias, L Bergenholm, M Liljeblad, SJ Daniels, ... HEPATOLOGY 72, 939-939, 2020 | 2 | 2020 |
| Model reduction of mechanism-based pharmacodynamic models and its link to classical drug effect models J Knöchel Dissertation, Potsdam, Universität Potsdam, 2019, 2019 | 2 | 2019 |
| Enhancing inclusivity in clinical trials: Model‐informed drug development for pregnant individuals in the era of personalized medicine A Dallmann, PL Bonate, J Burnham, B George, L Yao, J Knöchel CPT: Pharmacometrics & Systems Pharmacology 13 (11), 1824, 2024 | 1 | 2024 |
| Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide O Clewe, D Rekić, AL Quartino, B Carlsson, M Higashimori, L Wernevik, ... British Journal of Clinical Pharmacology, 2024 | 1 | 2024 |
| ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia A Hofherr, J Schumi, D Rekić, J Knöchel, CAM Nilsson, A Rudvik, ... Atherosclerosis 355, 28, 2022 | 1 | 2022 |
